Figure 1.
Figure 1. NK cell killing assay targeting ROSAKIT D816V cell line and NK cell activation assay targeting primary BM samples. (A) Normal donor NK cell–mediated killing of ROSAKIT D816V cells was evaluated in a 4-hour assay by measuring the number of remaining live ROSAKIT D816V cells using flow cytometry. (B) ROSAKIT D816V cell killing kinetics was measured by an IncuCyte imaging by evaluating the proportion of remaining live cells (representative of 3 studies). (C) Normal donor NK cell activation was measured against primary SM patient BM samples in the presence of indicted treatments with expression of CD107a, IFN-γ, and TNF-α production. *P ≤ .05; ****P < .0001. 161533, 161533 TriKE; CD16, anti-CD16 scFv; NT, no treatment.

NK cell killing assay targeting ROSAKIT D816Vcell line and NK cell activation assay targeting primary BM samples. (A) Normal donor NK cell–mediated killing of ROSAKIT D816V cells was evaluated in a 4-hour assay by measuring the number of remaining live ROSAKIT D816V cells using flow cytometry. (B) ROSAKIT D816V cell killing kinetics was measured by an IncuCyte imaging by evaluating the proportion of remaining live cells (representative of 3 studies). (C) Normal donor NK cell activation was measured against primary SM patient BM samples in the presence of indicted treatments with expression of CD107a, IFN-γ, and TNF-α production. *P ≤ .05; ****P < .0001. 161533, 161533 TriKE; CD16, anti-CD16 scFv; NT, no treatment.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal